How many drugs treat Waldenström macroglobulinemia?

Drug Landscape tracks 3 marketed treatments for Waldenström macroglobulinemia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/waldenstr-m-macroglobulinemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Waldenström macroglobulinemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Waldenström macroglobulinemia (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Waldenström macroglobulinemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Brukinsa	BGB-3111	Beigene Usa Inc	Kinase Inhibitor [EPC]	Tyrosine-protein kinase BTK	2019-01-01
Imbruvica	ibrutinib	AbbVie	Kinase Inhibitor [EPC]	Tyrosine-protein kinase Blk	2013-01-01
Imbruvica	Imbruvica	Rabin Medical Center		Nuclear receptor subfamily 4 group A member 3, Platelet glycoprotein VI, Serine/threonine-protein kinase LATS1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AbbVie · 1 drug in Waldenström macroglobulinemia
Beigene Usa Inc · 1 drug in Waldenström macroglobulinemia
Rabin Medical Center · 1 drug in Waldenström macroglobulinemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Waldenström macroglobulinemia:

Cite this brief

Drug Landscape (2026). Waldenström macroglobulinemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/waldenstr-m-macroglobulinemia. Accessed 2026-06-10.

Waldenström macroglobulinemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing